Business Context and Reporting Period
This Form 8-K was filed by Inotek Pharmaceuticals Corporation (not Rocket Pharmaceuticals, Inc.) on July 16, 2015. The report discloses the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance rather than financial performance.
Material Changes
The primary material change is the election of Richard N. Spivey, PharmD, PhD, as a new Class I independent director. Dr. Spivey brings significant regulatory and R&D experience from previous roles at Allergan, Meda AB, Pfizer, and Merck.
Compensation and Governance Details
- Stock Option Grant: Dr. Spivey was granted an option to purchase 24,000 shares of Common Stock at an exercise price of $5.32 per share (fair market value on the grant date).
- Vesting Schedule: 25% of shares vest on the one-year anniversary of the grant date; the remaining shares vest monthly (1/36th) thereafter, contingent on continued service.
- Committee Assignment: Dr. Spivey was appointed to the Nominating and Corporate Governance Committee.
- Indemnification: An indemnification agreement was executed in the standard form used for existing directors.
Investor Verification Checklist
- Verify the current stock price relative to the $5.32 exercise price granted to the new director.
- Confirm the total number of outstanding shares to assess the dilution impact of the 24,000 share option grant.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Check for any subsequent press releases regarding the new director's specific contributions or strategic initiatives.